These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3344411)

  • 1. [Treatment of neoplastic hypercalcemia using single-infusion diphosphonate].
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    Schweiz Med Wochenschr; 1988 Jan; 118(3):77-81. PubMed ID: 3344411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    J Clin Oncol; 1988 May; 6(5):762-8. PubMed ID: 3367184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P; Thiébaud D; Perey L; von Fliedner V
    Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate].
    Tubiana-Hulin M; de Vernejoul MC; Brière M; Miravet L; Clavel B
    Presse Med; 1984 Feb; 13(8):483-6. PubMed ID: 6230630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate.
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    J Bone Miner Res; 1986 Dec; 1(6):555-62. PubMed ID: 3503561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate.
    Thiébaud D; Jacquet AF; Burckhardt P
    Arch Intern Med; 1990 Oct; 150(10):2125-8. PubMed ID: 2222097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy.
    Thiébaud D; Portmann L; Jaeger P; Jacquet AF; Burckhardt P
    Bone; 1986; 7(4):247-53. PubMed ID: 3768203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia.
    Mannix KA; Carmichael J; Harris AL; Cantwell BM
    Cancer; 1989 Sep; 64(6):1358-61. PubMed ID: 2766228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parenteral diphosphonates for treating malignant hypercalcemia.
    Jung A; van Ouwenaller C; Chantraine A; Courvoisier B
    Cancer; 1981 Oct; 48(8):1922-5. PubMed ID: 6456809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): respective role of kidney and bone.
    Thiebaud D; Jaeger P; Burckhardt P
    J Bone Miner Res; 1990 Mar; 5(3):221-6. PubMed ID: 2333780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.
    Jacobs TP; Siris ES; Bilezikian JP; Baquiran DC; Shane E; Canfield RE
    Ann Intern Med; 1981 Mar; 94(3):312-6. PubMed ID: 6452846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy.
    Zysset E; Ammann P; Jenzer A; Gertz BJ; Portmann L; Rizzoli R; Jaquet-Müller F; Pryor-Tillotson S; Bonjour JP; Burckhardt P
    Bone Miner; 1992 Sep; 18(3):237-49. PubMed ID: 1392697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate.
    Shane E; Jacobs TP; Siris ES; Steinberg SF; Stoddart K; Canfield RE; Bilezikian JP
    Am J Med; 1982 Jun; 72(6):939-44. PubMed ID: 6211978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
    Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
    Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two parenteral diphosphonates in hypercalcemia of malignancy.
    Jung A
    Am J Med; 1982 Feb; 72(2):221-6. PubMed ID: 6460442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions.
    Body JJ; Magritte A; Seraj F; Sculier JP; Borkowski A
    J Bone Miner Res; 1989 Dec; 4(6):923-8. PubMed ID: 2692407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of amino-butylidene diphosphonate in hypercalcemia due to malignancy.
    Bickerstaff DR; O'Doherty DP; McCloskey EV; Hamdy NA; Mian M; Kanis JA
    Bone; 1991; 12(1):17-20. PubMed ID: 2054231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy.
    Davis JR; Heath DA
    Br J Clin Pharmacol; 1989 Sep; 28(3):269-74. PubMed ID: 2789920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy.
    Yates AJ; Murray RM; Jerums GJ; Martin TJ
    Aust N Z J Med; 1987 Aug; 17(4):387-91. PubMed ID: 3435316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pamidronate in the treatment of tumor-associated hypercalcemia].
    Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
    Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.